Drug intelligence / Profile preview

JS201

Development stage: Phase 1
Lead developer: Junshi Biosciences
Modality: Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

JS201 is a bifunctional fusion protein developed by Shanghai Junshi Biosciences. It simultaneously targets and blocks both PD-1 (programmed cell death protein 1) and TGF-β (transforming growth factor-beta) signaling pathways. By inhibiting these immunosuppressive pathways in the tumor microenvironment, JS201 aims to enhance the patient's immune response against tumor cells, reduce immune escape, and potentially overcome drug resistance. Its novel dual-targeting mechanism is designed to offer enhanced antitumor effects compared to single-target agents.

Targets

TGFB (GARP–latent transforming growth factor beta 1 complex)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on JS201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JS201.

Explore the full profile